NASDAQ:ANIX Anixa Biosciences Q2 2026 Earnings Report $3.06 +0.11 (+3.73%) As of 12:34 PM Eastern ProfileEarnings HistoryForecast Anixa Biosciences EPS ResultsActual EPS-$0.07Consensus EPS -$0.10Beat/MissBeat by +$0.03One Year Ago EPSN/AAnixa Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAnixa Biosciences Announcement DetailsQuarterQ2 2026Date6/10/2026TimeAfter Market ClosesConference Call DateWednesday, June 10, 2026Conference Call Time7:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Anixa Biosciences Earnings HeadlinesAnixa Biosciences Reports Stable Disease In Ovarian Cancer CAR-T TrialOctober 5 at 11:44 AM | rttnews.comAnixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical TrialOctober 5 at 8:15 AM | prnewswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 6 at 1:00 AM | Porter & Company (Ad)Anixa Biosciences, Inc. Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical TrialOctober 3 at 9:57 AM | marketscreener.comMAnixa Treats Second Patient At Highest Dose In Ovarian Cancer CAR-T StudyOctober 1, 2026 | rttnews.comAnixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical TrialOctober 1, 2026 | prnewswire.comSee More Anixa Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anixa Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anixa Biosciences and other key companies, straight to your email. Email Address About Anixa BiosciencesAnixa Biosciences (NASDAQ:ANIX), Inc. is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. Rather than marketing a broad portfolio of commercial products, the company concentrates on advancing novel therapies through research collaborations and clinical development. Anixa’s cancer programs include a breast cancer vaccine intended to target alpha-lactalbumin, a protein associated with certain breast cancers. The program is being developed in collaboration with researchers at Cleveland Clinic. The company has also pursued an ovarian cancer vaccine program and cellular immunotherapy approaches, including chimeric antigen receptor T-cell (CAR-T) technologies designed to improve the treatment of solid tumors. The company’s activities are primarily centered in the United States and are conducted through partnerships with academic and medical research institutions. Anixa was previously known as ITUS Corporation before adopting its current name. Amit Kumar, Ph.D., serves as chairman and chief executive officer.View Anixa Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AI Chip Demand Gives Linde a New Growth Catalyst3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street Divided Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
